hVIVO Beheer

Beheer criteriumcontroles 4/4

De CEO hVIVO is Mo Khan, benoemd in Feb2022, heeft een ambtstermijn van 2.75 jaar. De totale jaarlijkse vergoeding van { bedraagt £ 621.00K, bestaande uit 49% salaris en 51% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.077% van de aandelen van het bedrijf, ter waarde € 125.43K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 3.5 jaar.

Belangrijke informatie

Mo Khan

Algemeen directeur

UK£621.0k

Totale compensatie

Percentage CEO-salaris	49.0%
Dienstverband CEO	2.8yrs
Eigendom CEO	0.08%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	3.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Mo Khan's beloning veranderd ten opzichte van hVIVO's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	UK£17m
Mar 31 2024	n/a	n/a	UK£17m
Dec 31 2023	UK£621k	UK£304k	UK£16m
Sep 30 2023	n/a	n/a	UK£9m
Jun 30 2023	n/a	n/a	UK£3m
Mar 31 2023	n/a	n/a	UK£1m
Dec 31 2022	UK£592k	UK£260k	-UK£776k

Compensatie versus markt: De totale vergoeding ($USD 780.42K ) Mo } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 786.80K ).

Compensatie versus inkomsten: De vergoeding van Mo is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Mo Khan (55 yo)

2.8yrs

Tenure

UK£621,000

Compensatie

Dr. Yamin Mohammed Khan, also known as Mo, serves as Chief Executive Officer at hVIVO plc (formerly known as Open Orphan Plc) since February 24, 2022 and also serves as its Director since 2022. He was Inde...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yamin Khan	CEO & Director	2.8yrs	UK£621.00k	0.077% € 125.4k
Stephen Pinkerton	CFO & Executive Director	2.1yrs	UK£274.00k	geen gegevens
Andrew Catchpole	Chief Scientific Officer	no data	geen gegevens	geen gegevens
Teja Marathe-Sarvadikar	Head of QA	2.8yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van CRO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yamin Khan	CEO & Director	3.1yrs	UK£621.00k	0.077% € 125.4k
Stephen Pinkerton	CFO & Executive Director	2.1yrs	UK£274.00k	geen gegevens
Brendan Buckley	Member of Advisory Board & Non-Executive Director	no data	UK£45.00k	0.59% € 962.1k
Cathal Friel	Chairman of the Board	4.8yrs	UK£216.00k	geen gegevens
Martin Gouldstone	Independent Non-Executive Director	2.4yrs	UK£45.00k	geen gegevens
Elaine Sullivan	Independent Non-Executive Director	4yrs	UK£45.00k	geen gegevens
John Oxford	Chair of Advisory Board	4.8yrs	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CRO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

hVIVO Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

hVIVO plc, Annual General Meeting, May 13, 2024

Less than half of directors are independent

Open Orphan plc Announces Chief Financial Officer Changes

Open Orphan plc, Annual General Meeting, Jul 05, 2022

Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive Director

Less than half of directors are independent

Recent updates

hVIVO plc to Report First Half, 2024 Results on Sep 10, 2024

hVIVO Proposes Cancellation of Admission to Trading on Euronext Growth

hVIVO plc, Annual General Meeting, May 13, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: UK£0.024 (vs UK£0.001 loss in FY 2022)

hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024

hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.

hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.

Now 22% undervalued

hVIVO plc Signs £6.3 Million Human Challenge Study Model

hVIVO plc Increases Revenue Guidance for 2023

hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023

hVIVO plc to Develop Human Metapneumovirus Challenge Model

Full year 2022 earnings released: UK£0.001 loss per share (vs UK£0 in FY 2021)

Forecast to breakeven in 2023

hVIVO plc Provides Earnings Guidance for the Full Year 2022

Forecast breakeven date pushed back to 2023

hVIVO plc Announces Publication of Imutex Phase I Data

Now 20% undervalued

Less than half of directors are independent

Open Orphan plc Announces Chief Financial Officer Changes

Open Orphan plc Announces Positive Data from Peer-Reviewed Study Evaluating the in Vitro Efficacy of Flu-V

First half 2022 earnings released: EPS: UK£0 (vs UK£0.002 in 1H 2021)

Open Orphan plc Reiterates Revenue Guidance for the Full Year of 2022

Open Orphan Plc to Report First Half, 2022 Results on Sep 08, 2022

Open Orphan plc, Annual General Meeting, Jul 05, 2022

Full year 2021 earnings released: EPS: UK£0 (vs UK£0.018 loss in FY 2020)

Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive Director

Open Orphan plc to Report Fiscal Year 2021 Results on Jun 07, 2022

Less than half of directors are independent

Open Orphan plc Announces Characterisation Study Results in Nature Medicine

Open Orphan plc Appoints Yamin 'Mo' Khan as Chief Executive Officer

First half 2021 earnings released: EPS UK£0.002 (vs UK£0.012 loss in 1H 2020)

Executive Chairman recently bought €352k worth of stock

Full year 2020 earnings released: UK£0.018 loss per share (vs UK£0.034 loss in FY 2019)

New 90-day high: €0.35

Open Orphan plc Announces Ethics Approval for Covid-19 Human Challenge Study

Open Orphan Plc's Subsidiary Venn Life Sciences Announces Contract Extension with Carna Biosciences

New 90-day high: €0.33

Open Orphan plc Announces Contract Renewal with Top-3 Pharmaceutical Client Extending Its Consultancy Services to End of December 2021

Open Orphan plc Announces Board Changes, Effective on December 31, 2020

Open Orphan plc Announces the Signs of A £2.5 Million Contract by hVIVO

New 90-day high: €0.21

New 90-day high: €0.20

Open Orphan plc Announces £4.3 Million Contract to Conduct Human Viral Challenge Study

Open Orphan plc to Report First Half, 2020 Results on Sep 30, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd